Latigo Biotherapeutics Inc

Chart & performance

D1W1MN

P/E

—

P/S

—

EPS

Vol. 1Y

—

Shs. 5Y

—

Rev. 5Y

Div Yld LY

—

Div Yld TTM

—

Revenues

Net income

CFO

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.

Key people

Nancy Stagliano

Chairman of the Board

Desmond Padhi

Interim Chief Executive Officer, Director

Bryan Moyer

Co-Founder, Senior Vice President - Discovery

Holly Carlisle

Vice President - Translational Science

Mike Kaufman

Vice President - Chemistry

URL

https://latigobio.com

IPO date

Aug 07, 2026

Employees

Domiciled in

Incorporated in

Valuation

No data to show